Nothing Special   »   [go: up one dir, main page]

JP2010530897A5 - - Google Patents

Download PDF

Info

Publication number
JP2010530897A5
JP2010530897A5 JP2010513457A JP2010513457A JP2010530897A5 JP 2010530897 A5 JP2010530897 A5 JP 2010530897A5 JP 2010513457 A JP2010513457 A JP 2010513457A JP 2010513457 A JP2010513457 A JP 2010513457A JP 2010530897 A5 JP2010530897 A5 JP 2010530897A5
Authority
JP
Japan
Prior art keywords
deuterium
compound
positions represented
compound according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010513457A
Other languages
English (en)
Other versions
JP5587184B2 (ja
JP2010530897A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/067732 external-priority patent/WO2008157786A1/en
Publication of JP2010530897A publication Critical patent/JP2010530897A/ja
Publication of JP2010530897A5 publication Critical patent/JP2010530897A5/ja
Application granted granted Critical
Publication of JP5587184B2 publication Critical patent/JP5587184B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (7)

  1. 構造式Ｉを有する化合物、またはその医薬上許容し得る塩、溶媒和物もしくはプロドラッグ；
    Figure 2010530897
    （Ｉ）
    式中：
    Ｒ１、Ｒ２、Ｒ３、Ｒ４、Ｒ５、Ｒ６、Ｒ７、Ｒ８、Ｒ９、Ｒ１０、およびＲ１１は、水素および重水素からなる群から独立して選択され、
    Ｒ１、Ｒ２、Ｒ３、Ｒ４、Ｒ５、Ｒ６、Ｒ７、Ｒ８、Ｒ９、Ｒ１０、およびＲ１１のうちの少なくとも１つは、重水素であり、
    Ｒ７、Ｒ８、Ｒ９、Ｒ１０、およびＲ１１が重水素である場合、Ｒ１、Ｒ２、Ｒ３、Ｒ４、Ｒ５、およびＲ６のうちの少なくとも一つは重水素である。
  2. 前記化合物は、
    Figure 2010530897
    またはその医薬上許容し得る塩、溶媒和物、もしくはプロドラッグからなる群から選択される、請求項１に記載の化合物。
  3. Ｄとして表される前記位置のそれぞれは、少なくとも９８％の重水素濃縮を有する、請求項２に記載の化合物。
  4. Ｄとして表される前記位置のそれぞれは、少なくとも９０％の重水素濃縮を有する、請求項２に記載の化合物。
  5. Ｄとして表される前記位置のそれぞれは、少なくとも５０％の重水素濃縮を有する、請求項２に記載の化合物。
  6. Ｄとして表される前記位置のそれぞれは、少なくとも１％の重水素濃縮を有する、請求項２に記載の化合物。
  7. 前記化合物は、
    Figure 2010530897
     またはその医薬上許容し得る塩、またはその溶媒和物からなる群から選択される、請求項２から６いずれか一項に記載の化合物。
JP2010513457A 2007-06-20 2008-06-20 繊維症阻害剤としての置換ｎ−アリールピリジノン Active JP5587184B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94513607P 2007-06-20 2007-06-20
US60/945,136 2007-06-20
PCT/US2008/067732 WO2008157786A1 (en) 2007-06-20 2008-06-20 Substituted n-aryl pyridinones as fibrotic inhibitors

Publications (3)

Publication Number Publication Date
JP2010530897A JP2010530897A (ja) 2010-09-16
JP2010530897A5 true JP2010530897A5 (ja) 2011-08-04
JP5587184B2 JP5587184B2 (ja) 2014-09-10

Family

ID=39731521

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010513457A Active JP5587184B2 (ja) 2007-06-20 2008-06-20 繊維症阻害剤としての置換ｎ−アリールピリジノン

Country Status (13)

Country Link
US (6) US8383823B2 (ja)
EP (1) EP2170828B1 (ja)
JP (1) JP5587184B2 (ja)
KR (2) KR101767849B1 (ja)
CN (2) CN101842355A (ja)
AU (1) AU2008265595B2 (ja)
CA (1) CA2691379C (ja)
DK (1) DK2170828T3 (ja)
ES (1) ES2400026T3 (ja)
HK (1) HK1214251A1 (ja)
IL (1) IL202840A (ja)
NZ (1) NZ599643A (ja)
WO (1) WO2008157786A1 (ja)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
CN101842355A (zh) 2007-06-20 2010-09-22 奥斯拜客斯制药有限公司 作为纤维化抑制剂的取代的n-芳基吡啶酮
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
US20090131485A1 (en) * 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
US20110313004A1 (en) * 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
AU2010248758A1 (en) * 2009-05-15 2011-11-24 Intermune, Inc. Methods of treating HIV patients with anti-fibrotics
TWI434833B (zh) * 2009-06-03 2014-04-21 Intermune Inc 用於合成吡非尼酮（ｐｉｒｆｅｎｉｄｏｎｅ）的改良方法
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
CN101921225B (zh) * 2009-06-11 2013-04-03 北京凯得尔森生物技术有限公司 吡啡尼酮类化合物、其制备方法和应用
CN102869775A (zh) 2009-09-30 2013-01-09 哈佛大学校长及研究员协会 通过调节自噬抑制基因产物调节自噬的方法
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
HUE058753T2 (hu) * 2011-01-31 2022-09-28 Avalyn Pharma Inc Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik
WO2012122165A2 (en) * 2011-03-08 2012-09-13 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones
SG195110A1 (en) * 2011-05-25 2013-12-30 Intermune Inc Pirfenidone and anti-fibrotic therapy in selected patients
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CN113956315B (zh) 2011-09-08 2024-08-09 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
US20130150426A1 (en) 2011-11-22 2013-06-13 Intermune, Inc. Methods of diagnosing and treating idiopathic pulmonary fibrosis
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
EP2882426A1 (en) * 2012-08-13 2015-06-17 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for treatment of cystic fibrosis
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CA2819967C (en) * 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CA3114062A1 (en) 2013-03-13 2014-10-02 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
IL313113A (en) * 2013-03-13 2024-07-01 Sage Therapeutics Inc Neuroactive steroids, preparations and their uses
NZ760541A (en) 2014-01-10 2022-08-26 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
PE20161070A1 (es) * 2014-01-24 2016-11-19 Auspex Pharmaceuticals Inc N-aril piridinonas sustituidas
EA201691582A1 (ru) 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. Новые фармацевтические препараты
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
US20150284327A1 (en) * 2014-04-04 2015-10-08 Auspex Pharmaceuticals, Inc. Oxindole inhibitors of tyrosine kinase
WO2015171345A1 (en) * 2014-04-30 2015-11-12 Auspex Pharmaceuticals, Inc. N-aryl pyridinones modulators of fibrosis and/or collagen infiltration
EP3157528B1 (en) 2014-06-18 2023-09-13 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA2991311A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE053778T2 (hu) 2015-07-06 2021-07-28 Sage Therapeutics Inc Oxiszterinek és ezek alkalmazása
PT3319612T (pt) 2015-07-06 2021-08-24 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
CN105315198A (zh) * 2015-11-02 2016-02-10 重庆康乐制药有限公司 一种吡非尼酮的晶型及其制备方法
CN113144218A (zh) * 2015-11-25 2021-07-23 艾克萨姆治疗公司 包含美洛昔康的药物组合物
CN105330598B (zh) * 2015-12-02 2017-11-14 新发药业有限公司 一种吡非尼酮的制备方法
EP3432879B1 (en) * 2016-03-22 2021-01-06 Mayo Foundation for Medical Education and Research Using fatty acid synthase inhibitors to treat fibrosis
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
MA44526A (fr) 2016-04-01 2021-06-02 Sage Therapeutics Inc Oxystérols et leurs méthodes d'utilisation
KR20180126511A (ko) 2016-04-08 2018-11-27 큐어테크 바이오 에이비 고리-융합된 티아졸리노 2-피리돈, 이의 제조 방법 및 결핵의 치료 및/또는 예방에 있어서의 그 용도
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA3029900A1 (en) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018064649A1 (en) 2016-09-30 2018-04-05 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as nmda modulators
ES2968140T3 (es) 2016-10-18 2024-05-08 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
CA3234484A1 (en) 2016-10-18 2018-04-26 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN106748984A (zh) * 2016-11-22 2017-05-31 斯芬克司药物研发（天津）股份有限公司 6‑羟甲基‑1‑苯基吡啶‑2‑酮及其制备方法与应用
CA3108048A1 (en) * 2017-07-31 2019-02-07 Washington University Pirfenidone derivatives for modulation of b lymphocyte activity and organ protection
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
CN108285431B (zh) * 2018-03-23 2021-04-09 北京康蒂尼药业股份有限公司 一种吡非尼酮有关物质及其制备方法和用途
AU2019339536A1 (en) 2018-09-14 2021-04-29 Puretech Lyt 100, Inc. Deuterium-enriched pirfenidone and methods of use thereof
CA3175866A1 (en) * 2020-03-18 2021-09-23 Puretech Lyt 100, Inc. Methods of treating lymphedema with deupirfenidone
WO2022010925A1 (en) * 2020-07-06 2022-01-13 Puretech Lyt 100, Inc. Methods of treating diseases and disorders with deupirfenidone
CN114957106B (zh) * 2022-05-23 2024-01-30 湖北工程学院 药物吡非尼酮的流动相自动合成方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02215719A (ja) 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
ATE372966T1 (de) 1994-03-25 2007-09-15 Isotechnika Inc Verbesserung der effektivität von arzneimitteln duren deuterierung
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5962478A (en) * 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
ATE234299T1 (de) * 1999-12-03 2003-03-15 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
EP1134290A3 (en) * 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
US20030194748A1 (en) * 2000-05-29 2003-10-16 Tohru Nagasaki Method for labeling with tritium
EP1455813B1 (en) * 2001-12-18 2015-07-15 mondoBIOTECH AG Interferon gamma in combination with a diagnostic array for use in the improved treatment of idiopathic pulmonary fibrosis
CA2476012C (en) 2002-02-14 2011-04-19 Pharmacia Corporation Substituted pyridinones as modulators of p38 map kinase
CA2496577A1 (en) 2002-08-28 2004-03-11 Intermune, Inc. Combination therapy for treatment of fibrotic disorders
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
US20070072181A1 (en) 2003-02-28 2007-03-29 Blatt Lawrence M Combination therapy for treating alphavirus infection and liver fibrosis
WO2004105684A2 (en) 2003-05-16 2004-12-09 Intermune, Inc. Combination therapy for proliferative disorders
WO2005038056A1 (en) 2003-10-14 2005-04-28 Intermune, Inc. Combination therapy for the treatment of viral diseases
WO2005040758A2 (en) 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
JP4072623B2 (ja) 2004-03-09 2008-04-09 独立行政法人産業技術総合研究所 ピリジン−ｎ−オキシド類の製造方法
WO2005110478A2 (en) 2004-04-13 2005-11-24 Intermune, Inc. Combination therapy for treating fibrotic disorders
AP2007004244A0 (en) * 2005-05-10 2007-12-31 Intermune Inc Method of modulating stress-activated protein kinase system
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
EP2059241A1 (en) * 2006-09-05 2009-05-20 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US20080287508A1 (en) 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
CN101842355A (zh) 2007-06-20 2010-09-22 奥斯拜客斯制药有限公司 作为纤维化抑制剂的取代的n-芳基吡啶酮
US20090131485A1 (en) * 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20110313004A1 (en) 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
JP2012515800A (ja) 2009-01-26 2012-07-12 インターミューン， インコーポレイテッド 急性心筋梗塞および関連障害を処置するための方法
WO2010135972A1 (zh) 2009-05-25 2010-12-02 中南大学 1-(取代芳基)-5-三氟甲基-2-（1h）吡啶酮化合物及其盐的制备方法及其用途
WO2012122165A2 (en) 2011-03-08 2012-09-13 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones
SG195110A1 (en) 2011-05-25 2013-12-30 Intermune Inc Pirfenidone and anti-fibrotic therapy in selected patients
PE20161070A1 (es) 2014-01-24 2016-11-19 Auspex Pharmaceuticals Inc N-aril piridinonas sustituidas
WO2015171345A1 (en) 2014-04-30 2015-11-12 Auspex Pharmaceuticals, Inc. N-aryl pyridinones modulators of fibrosis and/or collagen infiltration

Similar Documents

Publication Publication Date Title
JP2010530897A5 (ja)
JP2010536766A5 (ja)
JP2009535462A5 (ja)
JP2011518833A5 (ja)
JP2007302689A5 (ja)
JP2012144574A5 (ja)
JP2010529994A5 (ja)
JP2011518775A5 (ja)
JP2013032389A5 (ja)
JP2014500861A5 (ja)
JP2006526031A5 (ja)
JP2011500769A5 (ja)
JP2009545527A5 (ja)
JP2009502793A5 (ja)
JP2010501534A5 (ja)
JP2010520214A5 (ja)
JP2009149903A5 (ja)
JP2007519721A5 (ja)
JP2010001302A5 (ja)
JP2010526814A5 (ja)
JP2009535358A5 (ja)
JP2010504343A5 (ja)
JP2010535870A5 (ja)
JP2010504908A5 (ja)
JP2011510079A5 (ja)